Wyeth (Madison, NJ) has received FDA approval for Tygacil?a novel intravenous (IV) antibiotic. The product has a broad spectrum of antimicrobial activity, including activity against the drug-resistant bacteria known as methicillin-resistant Staphylococcus aureus. Tygacil is indicated for the treatment of complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI) in adults. The product can be used as empiric monotherapy to treat a variety of cIAI and cSSSI, both hospital- and community-acquired, including complicated appendicitis, infected burns, intra-abdominal abscesses, deep soft tissue infections, and infected ulcers. The product does not require dosage adjustment in patients with impaired renal function. The recommended dosage regimen for Tygacil is an initial dose of 100 mg, followed by 50 mg every 12 hours. IV infusions should be administered for approximately 30 to 60 minutes every 12 hours. The recommended duration of treatment with Tygacil for cIAI or cSSSI is 5 to 14 days. The product is supplied in single-dose 5-mL glass vials. For more information, visit www.tygacil.com or www.wyeth.com.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs